We are live on
!
Find out more
BCM
Bronte Capital Management Portfolio holdings
AUM
$931M
1-Year Est. Return
47.97%
This Fund
S&P 500
This Quarter
Est. Return
+8.4%
1 Year Est. Return
+47.97%
3 Year Est. Return
+122.73%
5 Year Est. Return
+132.88%
10 Year Est. Return
–
AUM
$931M
AUM Growth
-$78.8M
(-7.8%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-11.56%
Top 10 Holdings %
Top 10 Hldgs %
71.82%
Holding
69
New
15
Increased
8
Reduced
33
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$17.8M |
| 2 |
Brown-Forman Class B
BF.B
|
+$12.5M |
| 3 |
iShares Core S&P Small-Cap ETF
IJR
|
+$3.16M |
| 4 |
Revolution Medicines
RVMD
|
+$2.74M |
| 5 |
Tyler Technologies
TYL
|
+$2.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Interactive Brokers
IBKR
|
+$33.1M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$27.5M |
| 3 |
iShares Russell 2000 Growth ETF
IWO
|
+$11.8M |
| 4 |
Herbalife
HLF
|
+$8.5M |
| 5 |
Pinterest
PINS
|
+$7.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.01% |
| 2 | Miscellaneous | 17.74% |
| 3 | Communication Services | 15.44% |
| 4 | Healthcare | 13.95% |
| 5 | Consumer Staples | 10.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Coherus Oncology
CHRS
$190M
| $21.4K | ﹤0.01% |
15,262
-4,020
| -21% | -$6.56K |
|
52
Milestone Pharmaceuticals
MIST
$114M
| $19.3K | ﹤0.01% |
14,390
+3,976
| +38% | +$6.36K |
|
53
Gossamer Bio
GOSS
$73M
| $11.2K | ﹤0.01% |
+847
| New | +$18.9K |
|
|
54
CALL
Brown-Forman Class A
BF.A
$12.3B
| – | – |
-493,902
| Closed | -$13.1M |
|
55
Caribou Biosciences
CRBU
$140M
| – | – |
-15,627
| Closed | -$29.7K |
|
56
Invivyd
IVVD
$220M
| – | – |
-11,012
| Closed | -$14.3K |
|
|
57
CALL
iShares Russell 2000 Growth ETF
IWO
$14.2B
| – | – |
-4,400
| Closed | -$1.38M |
|
|
58
iShares Russell 2000 Growth ETF
IWO
$14.2B
| – | – |
-37,542
| Closed | -$11.8M |
|
59
James River Group Holdings
JRVR
$175M
| – | – |
-338,961
| Closed | -$2.14M |
|
60
CALL
Nektar Therapeutics
NKTR
$2.33B
| – | – |
-202,500
| Closed | -$14.6M |
|
|
61
Pinterest
PINS
$10.4B
| – | – |
-430,950
| Closed | -$7.9M |
|
62
Pliant Therapeutics
PLRX
$70M
| – | – |
-18,613
| Closed | -$23.5K |
|
63
Rani Therapeutics
RANI
$98.3M
| – | – |
-14,868
| Closed | -$10.9K |
|
64
Sally Beauty Holdings
SBH
$1.48B
| – | – |
-220,737
| Closed | -$3.06M |
|
65
Fractyl Health
GUTS
$94M
| – | – |
-16,905
| Closed | -$7.74K |
|
Similar funds
AG
ACM
SAM
NS
PA
ACM
CICI
CAM
Bronte Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Bronte Capital Management held 69 positions worth $931M, down 7.8% from $1.01B the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Bronte Capital Management withdrew a net $108M in Q2 2026, closing 12 positions and reducing 33 holdings. Its most notable exit was iShares Russell 2000 Growth ETF, an estimated $11.8M position sold in full.
By sector, the portfolio is most concentrated in Financials at 23% of assets, up from 23% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Bronte Capital Management opened a new position in Brown-Forman Class B worth $12.4M.
- Bronte Capital Management's largest Q2 2026 buy was Brown-Forman Class B: 464,313 shares worth $12.4M.
- Bronte Capital Management added most to Walt Disney in Q2 2026, an estimated $17.8M increase.
- Bronte Capital Management's biggest Q2 2026 reduction was Interactive Brokers, cutting an estimated $33.1M.
- Bronte Capital Management fully exited iShares Russell 2000 Growth ETF in Q2 2026, selling an estimated $11.8M.
- Bronte Capital Management's ten largest holdings make up 72% of its $931M portfolio in Q2 2026.
- Bronte Capital Management opened 15 new positions and closed 12 in Q2 2026.
- Bronte Capital Management's portfolio value fell 7.8% quarter-over-quarter to $931M.
Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.